Tenax Therapeutics (NASDAQ:TENX) Posts Quarterly Earnings Results, Beats Estimates By $0.34 EPS

Tenax Therapeutics (NASDAQ:TENX) announced its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.34, Zacks reports.

Tenax Therapeutics Stock Performance

Shares of Tenax Therapeutics stock opened at $6.26 on Wednesday. The company has a fifty day simple moving average of $6.44 and a 200-day simple moving average of $5.39. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.89.

Wall Street Analyst Weigh In

TENX has been the topic of several analyst reports. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. StockNews.com started coverage on Tenax Therapeutics in a research note on Friday, March 21st. They set a “sell” rating on the stock. Finally, Leerink Partners set a $20.00 target price on Tenax Therapeutics in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.